Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Development of Skin-Penetrating Lipid Nanoparticles for Needle-Free Vaccination
FY 2025-26
Summary
Background and Rationale: Injectable mRNA vaccines have demonstrated transformative potential in infectious disease prevention. These vaccines may further benefit from needle-free transdermal delivery, which eliminates needle anxiety and removes the risk of cross-contamination. However, skin penetration is limited by the large size and negative charge of mRNA molecules. To address this, lipid nanoparticles (LNPs) may be engineered to enhance transdermal RNA transport through the inclusion of skin penetration enhancers. Commonly used in the cosmetics industry, penetration enhancers remain unexplored as LNP components. Development of penetration-enhanced LNPs represents a promising path towards needle-free mRNA vaccination. Hypothesis: Skin-penetrating LNPs will improve transdermal mRNA delivery and elicit a strong immune response, providing a viable strategy for developing needle-free vaccines. Experimental Design: A library of LNPs incorporating lipid-like penetration enhancers such as limonene will be synthesized and characterized for encapsulation efficiency, size and polydispersity. Transfection efficiency will be screened in vitro using flow cytometry, and top-performing candidates will be identified based on protein expression levels. Lead formulations will then be screened ex vivo by fluorescence microscopy to determine penetration depth. Lead ex vivo LNP formulations will be tested in vivo by delivering OVA-encoding mRNA transdermally, and vaccine efficacy will be quantified through anti-OVA antibody titers measured using ELISA. Expected Outcomes and Impact: This research will identify a library of transdermal LNP formulations induce strong immune responses in mice, providing a foundation for the development of transdermal mRNA-LNP vaccines.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572633
Name
Giles Adam
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of Skin-Penetrating Lipid Nanoparticles for Needle-Free Vaccination
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cosmetics; Dermatology; Drug Delivery; Lipid Nanoparticle; Mrna Vaccine; Nanomedicine; Needle-Free; Painless; Penetration Enhancers; Transdermal Vaccine
Abstract
Background and Rationale: Injectable mRNA vaccines have demonstrated transformative potential in infectious disease prevention. These vaccines may further benefit from needle-free transdermal delivery, which eliminates needle anxiety and removes the risk of cross-contamination. However, skin penetration is limited by the large size and negative charge of mRNA molecules. To address this, lipid nanoparticles (LNPs) may be engineered to enhance transdermal RNA transport through the inclusion of skin penetration enhancers. Commonly used in the cosmetics industry, penetration enhancers remain unexplored as LNP components. Development of penetration-enhanced LNPs represents a promising path towards needle-free mRNA vaccination. Hypothesis: Skin-penetrating LNPs will improve transdermal mRNA delivery and elicit a strong immune response, providing a viable strategy for developing needle-free vaccines. Experimental Design: A library of LNPs incorporating lipid-like penetration enhancers such as limonene will be synthesized and characterized for encapsulation efficiency, size and polydispersity. Transfection efficiency will be screened in vitro using flow cytometry, and top-performing candidates will be identified based on protein expression levels. Lead formulations will then be screened ex vivo by fluorescence microscopy to determine penetration depth. Lead ex vivo LNP formulations will be tested in vivo by delivering OVA-encoding mRNA transdermally, and vaccine efficacy will be quantified through anti-OVA antibody titers measured using ELISA. Expected Outcomes and Impact: This research will identify a library of transdermal LNP formulations induce strong immune responses in mice, providing a foundation for the development of transdermal mRNA-LNP vaccines.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Giles, Adam
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~